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Abstract
Background: The Global Network for Women’s and Children’s Health Research undertook a cluster-randomized trial
to assess the impact of a multi-faceted intervention to identify women at high-risk of preterm birth at all levels of
care, to administer corticosteroids to women and refer for facility delivery compared with standard care. Of the
seven sites that participated in the ACT trial, only two sites had statistically significant reductions in the neonatal
mortality among the target group of <5th percentile infants, and of the two, Guatemala’s improvement in neonatal
mortality was by far the largest.
Methods: We used data available from the ACT trial as well as pretrial data in an attempt to understand why
neonatal mortality may have decreased in the intervention clusters in <5th percentile infants in Chimaltenango,
Guatemala. The intervention and control clusters were compared in regards to ACS use, the various types of
medical care, outcomes in facility and community births and among births in various birth weight categories.
Results: Neonatal mortality decreased to a greater extent in the intervention compared to the control clusters in
the <5th percentile infants in Guatemala during the ACT Trial. ACS use for the <5th percentile infants in the
intervention clusters was 49.1 % compared to 13.8 % in the control clusters. Many measures of the quality of
obstetric and neonatal care improved to a greater extent in the intervention compared to the control clusters
during the trial. Births in facilities and births weighing 1500 to 2500 g had the greatest reduction in neonatal
mortality.
Conclusions: The combination of improved care and greater ACS use may potentially account for the observed
difference in neonatal mortality between the intervention and control clusters.
Trial registration: Clinicaltrials.gov: NCT01084096.
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Background
In high-resource countries, antenatal corticosteroids (ACS)
given to the mother in the week prior to a preterm birth
<34 weeks is associated with a reduction in respiratory dis-
tress syndrome, intraventricular hemorrhage, necrotizing
enterocolitis and neonatal death [1–3]. Because few studies
have evaluated the effectiveness of ACS in low-middle in-
come countries (LMIC), from 2012 to 2014, the Eunice
Kennedy Shriver National Institute of Child Health and Hu-
man Development (NICHD)’s Global Network for Women
and Children’s Health Research conducted the Antenatal
Corticosteroids Trial (ACT). This trial was carried out in
Chimaltenango, Guatemala and 6 other sites in LMIC
(Argentina, Kenya, Zambia, Pakistan and India [2 sites]).
ACT was a cluster randomized trial which tested whether
an intervention including birth attendant training and the
provision of kits with ACS increased the use of ACS, and if
use increased, whether the intervention was effective in re-
ducing neonatal mortality and was safe [4]. Overall, the
intervention substantially increased the use of ACS in the
intervention clusters, but was not effective in reducing neo-
natal mortality in the targeted infants and was associated
with a small but significant increase in overall neonatal
mortality. However, two of the 7 sites had lower neonatal
mortality in the targeted less than 5th percentile infants in
the intervention compared to the control clusters and of
these two, the reduction in Guatemala was the greatest [5].
In Guatemala, the ACT study took place in the
Chimaltenango region, an area in the Western highlands
populated predominantly by indigenous peoples [6]. In
that region, the infant mortality is generally higher than in
other areas of Guatemala and has been associated with a
high percentage of home births cared for by traditional
birth attendants (TBAs) [7, 8]. For home births, pregnant
women at risk for preterm birth rarely receive ACS. While
ACS use is recommended by the Guatemala Ministry of
Health (MOH), there are no data on the rate of use within
hospitals.
In recent years, the Chimaltenango district hospital
(Hospital Nacional de Chimaltenango), which serves as a
referral hospital, has undergone extensive improvements.
As a national law to improve maternal and neonatal care
was implemented, there was a concerted effort by the
MOH to improve the quality of care in the community
health services and at this district hospital. The hospital,
which in 2010 had five obstetricians and five pediatricians,
as of 2015 had 11 obstetricians and 11 pediatricians on
staff. There are residency programs in both obstetrics and
gynecology and pediatrics, with 12 residents in each pro-
gram. There is a newborn care nursery with intensive care
and a referral system with ambulances available for trans-
port from other lower level health services in the district.
In addition, substantial effort has been directed to ensure
that TBAs identify and make early referrals of pregnancies
and deliveries, when needed, and to improve the overall
collaboration between community level and institutional
health personnel [8].
Thus, the Chimaltenango district hospital has many
similar capabilities to those of the hospitals in high in-
come countries, in which trials of ACS have shown
benefit [3, 9–11].
Since 2010, in the Chimaltenango district, births inside
a facility increased from one third to one half of the total
and were accompanied by measurable improvements in
the quality of care [12]. With these changes, there have
been substantial improvements in both the neonatal
mortality and stillbirth rates in the Chimaltenango area.
It is in this setting that the ACT study took place from
September 2012 to March 2014. The goal of this case
study was to explore the potential reasons for the lower
rate of neonatal mortality in the <5th percentile infants
in the intervention clusters compared to the control
clusters in the Chimaltenango region of Guatemala dur-
ing the ACT trial period.
Methods
The NICHD Global Network undertook a cluster-ran-
domized trial to assess the impact of a multi-faceted inter-
vention to identify women at high-risk of preterm birth at
all levels of care, to administer corticosteroids to women
and refer for facility delivery compared with standard care.
The methods for the ACT trial are described in detail else-
where [4, 5], but briefly, at each site, intervention and con-
trol study clusters were included as part of a prospective
Maternal Newborn Health Registry, in which study staff
sought to identify all pregnant women and enroll them
early in pregnancy and follow them through delivery
[13, 14]. Clusters were geographically defined and generally
included 300–500 pregnant women who delivered each
year. Following randomization, the trial staff aimed to train
all birth attendants within the intervention clusters on iden-
tifying signs of preterm birth, determining which mothers
were within the gestational age range to be eligible for ACS,
and transferring these mothers to a hospital to receive ACS.
In Guatemala, the trial occurred in 10 clusters in the
Chimaltenango Province, located 60 km from Guatemala
City, the capital of Guatemala. The MOH is the most
common provider of health care in the region and physi-
cians and nurses provide care through a network of ten
health centers and 35 health posts. There is one single
referral hospital for the region. In this intervention, pre-
term birth was identified at the community level and/or
inside health services and women were referred to the
Chimaltenango hospital for delivery and care.
Outcomes
The outcome data were collected independently by trained
Registry Administrators in a prospective Maternal and
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Newborn Health (MNH) registry [13, 14]. The primary
outcome of the ACT trial was 28-day neonatal mortality
among <5th percentile birth weight infants (proxy for pre-
term birth due to poor gestational age dating). The <5th
percentile was based on the pre-trial rates and the
site-specific cut-off for Guatemala was 2,267 g. ACS
administration and suspected maternal infection were
secondary outcomes of the ACT trial. To define maternal
infection, we collected data on clinical symptoms and
process measures for a composite outcome of suspected
infection (but did not have confirmed maternal infection).
We also explored the relationship between ACT
treatment group and measures of delivery care, facility
characteristics, and neonatal infection. Facilities were
characterized as having cesarean section capabilities if
two or more women received a cesarean section at the
facility during the ACT trial period. Similarly, facility
neonatal care capabilities including bag and mask, and
oxygen or mechanical ventilation were determined in
the same manner. For newborn infection, we used the
Word Health Organization (WHO) Young Infants Clinical
Signs Study criteria [15, 16] to define possible severe bac-
terial infection (PSBI). PSBI was defined as an infant with
any of the following: breathing difficulty, feeding problems
(i.e., stopped suckling or feeding), high fever (>38 °C),
hypothermia (<35 °C), convulsions, and bleeding or
pus-like discharge from umbilicus. Finally, we calculated
28-neonatal mortality rates stratified by delivery location
and birth weight category.
Statistical analyses
The ACT trial was powered to detect a 30 % reduction
in 28-day neonatal mortality among <5th percentile birth
weight infants but the trial was not designed to conduct
country-specific analyses. A total of 10 defined geographic
clusters in Guatemala were randomized within five
randomization strata. Because one control cluster was
dropped early in the trial due to security reasons which
prevented study activities, we excluded both intervention
and control data from that stratum. The trial period in-
cluded births between September 2012 and March 2014
and used data for births occurring in 2010 as pretrial data.
Generalized linear models were used to evaluate the
relationship between ACT treatment group and 28-day
neonatal mortality and PSBI, and to develop point and
interval estimates of relative risk (RR) associated with
these risk factors. Additionally, we used a generalized
linear model with an identity link to test whether the
change in prevalence of specific prenatal and delivery
characteristics from the pretrial to the trial periods
differed by treatment group. For all models, general-
ized estimating equations were used to account for the
correlation of outcomes within cluster to develop ap-
propriate confidence intervals. Analyses were adjusted
for randomization strata. Descriptive statistics (fre-
quencies, percentages and rates per 1,000 live births)
are provided for treatments, morbidities, and 28-day
neonatal mortality. Analyses were performed by RTI
International with SAS versions 9.3 and 9.4 (SAS Institute,
Cary, NC, USA).
Approvals
The trial was reviewed and approved by the ethics com-
mittees at each site, the World Health Organization and
the NICHD. An independent data monitoring commit-
tee appointed by NICHD reviewed the progress of the
trial, as specified in the protocol. All women provided
informed consent prior to enrollment.
Results
Table 1 presents the relative risk (RR) and 95 % confi-
dence intervals (CI) for neonatal mortality in the <5th
percentile infants in the intervention compared to the
control clusters during the ACT trial by site. Of the 7
sites that participated in the ACT trial, only 2 sites had
significant reductions in 28 day neonatal mortality in the
targeted group of <5th percentile infants, and of the
two, Guatemala’s improvement was by far the largest.
The RR for neonatal death for <5th percentile infants
in Guatemala in the intervention clusters was 0.74
(0.68, 0.81), p = <.0001. None of the sites, including
Guatemala had an overall lower rate of neonatal mor-
tality in the intervention clusters.
Table 2 presents the percent of births that were <5th
percentile and the neonatal mortality rates in the pretrial
and trial periods. The percent of neonates classified as <5th
percentile was slightly lower in the intervention clusters
prior to the trial but became slightly higher during the trial.
The overall neonatal mortality was similar in the interven-
tion and control clusters prior to the trial (not surprising
Table 1 Relative risk and 95 % confidence intervals for neonatal
mortality by site for <5th percentile births and all births
Research Site <5th %ile births
RR (95 % CI)
All births
RR (95 % CI)
Zambia 1.43 (0.90, 2.28) 1.77 (1.42, 2.20)
Kenya 1.30 (0.94, 1.81) 1.47 (1.02, 2.12)
Belgaum, India 0.96 (0.75, 1.22) 1.13 (0.99, 1.27)
Nagpur, India 0.94 (0.72, 1.23) 1.36 (1.09, 1.71)
Pakistan 0.89 (0.80, 0.99) 0.93 (0.82, 1.07)
Argentina 1.60 (0.99, 2.58) 1.06 (0.54, 2.09)
Guatemala 0.74 (0.68, 0.81) 0.88 (0.73, 1.06)
Relative Risk (RR) for 28-day neonatal mortality comparing intervention to con-
trol groups by research site. RR with corresponding 95 % CIs and p-values were
calculated from generalized linear models accounting for the cluster-level vari-
ance and adjusted for randomization strata. For Guatemala we excluded data
from entire strata that included the cluster that could not participate due to
security concerns
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since the clusters were randomized in part based on the
pretrial neonatal mortality rates). During the trial, the
overall neonatal mortality was lower in the intervention
clusters, but not significantly so (21.7/1000 vs 26.1/1000,
RR 0.88 (0.73, 1.06), p = 0.1875).
We also compared the <5th percentile neonatal mor-
tality in the intervention and control clusters in the
period before the trial to the results during the trial. In
the control clusters the neonatal mortality in the <5th
percentile infants increased from 219/1000 live births to
235/1000 live births, while in the intervention clusters
the neonatal mortality in the <5th percentile infants fell
from 286/1000 to 183/1000. Therefore, neonatal mortal-
ity in the <5th percentile infants decreased substantially
from the pretrial period to the trial period in the inter-
vention clusters, but actually increased slightly in the
control clusters. And importantly, the significant differ-
ence in neonatal mortality in the <5th percentile infants
between the intervention and control clusters during the
trial was not due to a lower neonatal mortality in the
intervention clusters prior to the trial.
The use of ACS in the intervention and control clusters
in the overall population and in the <5th percentile births
during the ACT trial was compared. In the intervention
clusters, the overall use of ACS was 10.2 % compared to
1.0 % in the control clusters. For the <5th percentile in-
fants, in the intervention clusters, 49.1 % received ACS
compared to 13.8 % in the control clusters, nearly a four-
fold increase (data not shown).
We evaluated the characteristics of the women in the
intervention and control clusters during the trial (Table 3).
While similar percentages of women in both groups had
no education, more women in the intervention clusters
had secondary and university educations. Parity and age
distributions appeared similar in the intervention com-
pared to the control clusters. The rate of multiple births
was less than 1 % in both groups, but was higher in the
intervention clusters.
Next we evaluated some characteristics related to deliv-
ery care in the intervention and control clusters during
one year prior to the trial and then during the trial period
(Tables 4 and 5). First, in both the intervention and con-
trol clusters, many of the measures related to the quality
of obstetric care clearly improved over time, including the
use of hospitals for delivery, physician as the birth attend-
ant and the rate of cesarean delivery [8]. Prior to the trial
most of the characteristics evaluated, including hospital
delivery, physician attendance and cesarean section usage
were either similar between the intervention groups or the
higher levels of care favored the control clusters. However,
during the trial, these same measurements consistently
favored the intervention clusters and suggested that the
availability and usage of obstetric care improved to a
greater extent in the intervention than in the control
clusters. When we evaluated whether the change in care
between the pretrial period and the trial period differed
between the treatment and control groups, we found large
Table 2 Pretrial and trial data by group and period
Characteristic Pre trial Trial period, N (Rate/1000)
Intervention Control Intervention Control RR (95 % CI), p-value
Babies 2,053 2,321 3,800 3,978 –
Live births 2,007 (97.8) 2,271 (97.8) 3,725 (98.0) 3,905 (98.2) –
<5th percentile live births (% of live births) 77 (3.8) 105 (4.6) 197 (5.3) 166 (4.3) –
Neonatal death 28 daysa
Overall 59 (29.7) 68 (29.9) 81 (21.7) 102 (26.1) 0.88 (0.73, 1.06), p = 0.1875
<5th percentile 22 (285.7) 23 (219.0) 36 (182.7) 39 (234.9) 0.74 (0.68, 0.81), p = <.0001
aThe denominator for neonatal mortality is all live births. Of the 2,007 live births in the intervention group during the pre-trial period 21 missing 28-day status are
excluded from the denominator




Women, N 3,766 3,960
Maternal age, N (%) 3,765 3,960
<20 600 (15.9) 639 (16.1)
20–35 2,797 (74.3) 2,888 (72.9)
>35 368 (9.8) 432 (10.9)
Maternal education, N (%) 3,766 3,960
No formal education 720 (19.1) 811 (20.5)
Primary 2,239 (59.5) 2,604 (65.8)
Secondary 756 (20.1) 533 (13.5)
University + 51 (1.4) 12 (0.3)
Parity, N (%) 3,765 3,960
0 1,122 (29.8) 1,085 (27.4)
1 824 (21.9) 839 (21.2)
2 or more 1,819 (48.3) 2,036 (51.4)
Multiples 3,766 3,960
Yes 34 (0.9) 16 (0.4)
No 3,732 (99.1) 3,944 (99.6)
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Table 4 Prenatal and delivery characteristics by group and period
Characteristic Pre-trial period Trial period Crude Estimate of Change in









(95 % CI), p-valueb
Intervention Control Intervention Control Intervention Control
Deliveries, N 2,041 2,305 3,766 3,960
At least one antenatal care visit, (%) 98.7 97.3 99.2 99.2 0.5 1.9 −1.4 −1.72 (−4.00, 0.55),
p = 0.1379
Prenatal vitamins/iron, (%) 85.9 89.7 93.7 91.4 7.8 1.7 6.1 6.46 (2.02, 10.89),
p = 0.0043
Birth attendant, (%) 26.0 13.0 13.0 7.56 (−3.09, 18.20),
p = 0.1643
Physician 26.0 32.3 50.6 45.1
Nurse/Midwife/HW 1.7 0.2 3.1 0.5
TBA 72.1 67.1 45.7 53.9
Family/Other 0.2 0.4 0.6 0.6
Delivery mode, (%) −11.1 −7.1 −4.0 −2.21 (−8.17, 3.76),
p = 0.4689
Vaginal 87.9 87.5 76.8 80.4
C-section 12.1 12.5 23.2 19.6
BA used new gloves, (%) 98.5 97.6 99.3 99.0 0.8 1.4 −0.6 −0.53 (−2.02, 0.97),
p = 0.4894
aCrude change in prevalence = percentage during the trial period minus percentage during the pretrial period
bTest to assess whether the change between the pretrial and trial periods differed by treatment group. P-values calculated from generalized linear models
accounting for the cluster-level variance and adjusted for randomization strata
Table 5 Delivery location characteristics by group and period










(95 % CI), p-valuec
Intervention Control Intervention Control Intervention Control
Deliveries, N 2,041 2,305 3,766 3,960
Delivery location, (%) –
Hospital 24.9 29.8 46.8 44.3 21.9 14.5 7.4
Clinic 2.5 2.3 7.0 1.1 4.5 −1.2 5.7
Home/Other 72.6 67.9 46.2 54.6 −26.4 −13.3 −13.1
Birth at facility level (hospital or clinic), (%) 27.4 32.1 53.8 45.4 26.4 13.3 13.1 7.70 (−2.61, 18.01),
p = 0.1434
Birth at facility with C-section or any
neonatal care capabilitiesd, (%)
26.2 31.0 53.3 45.2 27.1 14.2 12.9 7.36 (−3.39, 18.12),
p = 0.1797
Birth at facility that has C-section
capabilities, (%)
26.1 31.0 47.5 40.5 21.4 9.5 11.9 –
Birth at facility that has bag and
mask capabilities, (%)
10.7 11.1 43.7 41.9 33.0 30.8 2.2 –
Birth at facility that has oxygen or
mechanical ventilation capabilities, (%)
20.8 26.6 47.4 42.6 26.6 16.0 10.6 –
aCrude change in prevalence = (percentage during the trial period minus percentage during the pretrial period)
bCrude difference in change in prevalence = (percentage during the trial period minus percentage during the pretrial period for the treatment group) minus
(percentage during the trial period minus percentage during the pretrial period for control group)
cTest to assess whether the change between the pretrial and trial periods differed by treatment group. The adjusted percent difference of the percent differences
is the estimate of the difference in changes in probability from pretrial to trial period for the given characteristic in the treatment arm minus changes in
probability from the pretrial to trial period for the given characteristic in the control arm. P-values were calculated from generalized linear models accounting for
the cluster-level variance and adjusted for randomization strata
dNeonatal care capabilities include bag and mask, oxygen or mechanical ventilation. Facilities with any of the capabilities are tested for differences between the
pretrial and trial periods by treatment group
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changes for use of vitamins and delivery by a trained
attendant that appeared to differ in a meaningful way
between the treatment groups; however, the only change
that showed a statistically significant difference between
treatment groups was vitamin usage (6.46 % (2.02,
10.89 %, p = 0.0043) (Table 4). The unadjusted difference
of the increase in prevalence in the treatment arm was
13 % more than the control arm (adjusted percent dif-
ference of the differences 7.56, 95 % CI −2.09, 18.20 %
p = 0.1643).
We also evaluated the capability of the facilities used
for deliveries in the intervention and control clusters in
the pretrial and trial periods (Table 5). Births in a facility
of any kind increased substantially in both the interven-
tion and control clusters, but to a greater extent in the
intervention clusters (adjusted difference in change in
prevalence of delivery in facility 7.70, 95 % CI −2.61,
18.01, p = 0.1434). When the capability of the facilities
was evaluated, there were again substantial improve-
ments from the pretrial to the trial period in births at fa-
cilities with cesarean section capabilities, bag and mask
capabilities for neonatal resuscitation and oxygen. When
the percent of births in facilities with any of those cap-
abilities was evaluated, there was a substantial increase
in these characteristics from the pretrial to the trial
period, but the increases were greater in the intervention
compared to the control clusters but the difference was
not statistically significant (adjusted difference in change
in prevalence 7.36, 95 % CI −3.39, 18.12, p = 0.1797).
We compared the overall neonatal mortality rates by
location of birth (home or facility) in the pretrial com-
pared to the trial period in the intervention and control
clusters (Table 6). In the home births, the mortality rates
were all between 21/1000 and 28/1000 in the pretrial
and trial periods. There was however, a small decrease in
the neonatal mortality rate in the control clusters from the
pre-trial to the trial period. (28/1000 to 23/1000). In the
facility births in the pretrial period the overall neonatal
mortality was considerably higher in the intervention
compared to the control clusters. However, there was a
substantial decrease in the neonatal mortality rate in the
facility births in the intervention clusters such that during
the trial the mortality rates in the intervention clusters
was 21.9/1000 births compared to 29.8 in the control clus-
ters. Furthermore, when we evaluated the rates of neonatal
mortality in the intervention compared to the control
clusters in facilities able to provide cesarean section, or
any neonatal care capability (bag and mask resuscitation,
oxygen or mechanical ventilation), the difference in
the neonatal mortality rate was substantial (22.1/1000
vs 30.0/1000 live births).
In Table 7 we compared the neonatal mortality within
each of the birth weight groups in the intervention and
control clusters during the trial period. Substantial dif-
ferences in mortality occurred in both the 1500–2499 g
group and in the ≥2500 g birth weight groups in the
intervention compared to the control clusters. Since the
5th percentile birth weight in Guatemala was 2267 g, and
since most of the births <2500 g weighed 1500 to
2499 g, there is reasonably good concordance between
the results by birth weight percentiles and by specific
birth weight groups.
Finally, we evaluated measures of maternal and neo-
natal infection during the trial in the intervention and
control clusters in the overall population and in the <5th
percentile births (Table 8). There were essentially no dif-
ferences in the maternal infection measure between the
intervention and control clusters in the entire popula-
tion or in the mothers of the <5th percentile babies. The
measure of neonatal infection among the intervention
group when compared to the control group was slightly
greater in both the entire population of newborns, and
in the <5th percentile babies but neither difference was
significant.
Discussion
First, we emphasize that because this is a secondary ana-
lysis from a single site of a multisite trial, the results are
exploratory in nature. We are presenting these data as a
case study, to explore factors related to the mothers, the
infants and the quality of care, including the use of ACS.
This analysis is an attempt to understand the outcomes
Table 6 Mortality rates by delivery location and period
Characteristica Pre-trial period Trial period
Intervention Control Intervention Control
Live births, N 2,007 2,271 3,725 3,905
Neonatal deaths <28d, N (Rate/1000) in home birth 21.4 27.8 21.6 23.0
Neonatal deaths <28d, N (Rate/1000) in facility (clinic or hospital) 52.0 34.4 21.9 29.8
Neonatal deaths <28d, N (Rate/1000) in facility with C-section or any neonatal care capabilitiesb 52.4 32.7 22.1 30.0
Note: The table provides rates for neonatal mortality by location of delivery. The event counts within clusters were too small to get reliable estimates of relative
risk for treatment versus control groups, or for probability differences for changes between the pretrial and trial periods by treatment group
aThe denominator for neonatal mortality is all live births. Of the 2,007 live births in the intervention group during the pre-trial period 21 are missing 28-day status
and are excluded from the denominator
bNeonatal care capabilities include bag and mask, oxygen or mechanical ventilation
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in Chimaltenango, Guatemala, which showed benefit in
the intervention clusters in the targeted <5th birth weight
percentile, differing from the overall findings of the ACT
trial. The intervention aimed at improving identification
of women likely to deliver preterm within 7 days and in
the appropriate gestational age range and to facilitate
appropriate use of antenatal corticosteroids for those
women. The results showed a significant reduction in
neonatal mortality in the <5th percentile infants in the
Guatemala site.
During the trial, in the intervention clusters, irrespective
of where delivery occurred (facility or home), the neonatal
mortality rates were lower than deliveries in control
clusters. However, the largest differences were observed in
facility births. The reduction in neonatal mortality in the
intervention clusters occurred in babies over 1500 g and
was greatest and significant in the < 5th percentile infants.
We explored various factors that could explain these dif-
ferences. The difference in neonatal mortality between the
intervention and control clusters was not explained by dif-
ferences in neonatal mortality in the pretrial period. We
found no large differences in the populations of the inter-
vention and control clusters; the proportion of births
below the 5th percentile and the characteristics of mothers
were similar overall in both groups during the trial.
During the ACT trial, the quantity of prenatal care did
not appear to be different between intervention and con-
trol clusters, although the use of vitamins was increased
in the intervention clusters. However, care at delivery
appeared better in intervention clusters including deliv-
ery at a hospital or clinic, delivery by a physician and
use of cesarean section, although the differences were
not different statistically. ACS use in the intervention
clusters was significantly higher than in the control clus-
ters, 49.1 % compared to 13.8 %. Evidence of maternal
or neonatal infection did not appear to be different be-
tween the two groups.
Conclusions
In conclusion, whether the improvement in care in the
intervention clusters compared to the control clusters
was due to the multipronged ACT intervention during
the ACT Trial or occurred independently is unknown.
In addition, the care available to pregnant women and
newborns in the Chimaltenango hospital appears to be
at a higher level than that available in many of the other
trial sites and in some respects approaches that seen in
high-income countries where most trials of ACS have
shown benefits. If the Guatemalan results did not occur
by chance, we suspect that the combination of improved
care and greater ACS use may account for the observed
difference in the <5th percentile neonatal mortality be-
tween the intervention and control clusters.
Table 7 Mortality rates by birth weight in intervention and
control clusters during the trial period among live births
Characteristics Trial period
Intervention Control
Live births, N 3,725 3,905
Mortality for births <1000 g
Births <1000 g, N 10 7
Neonatal deaths, N 9 7
Neonatal mortality < 28 days, n (rate/1000) 900 1000
Mortality for births 1000–1499 g
Births 1000–1499 g, N 22 20
Neonatal deaths, N 14 10
Neonatal mortality < 28 days, n (rate/1000) 636 500
Mortality rates for births 1500–2499 g
Births 1500–2499 g, N 487 454
Neonatal deaths, N 20 33
Neonatal mortality < 28 days, n (rate/1000) 41.1 72.7
Mortality rates for births≥ 2500 g
Births≥ 2500 g, N 3,206 3,424
Neonatal deaths, N 38 52
Neonatal mortality < 28 days, n (rate/1000) 11.9 15.2
Note: The table provides frequencies and rates for neonatal mortality by birth
weight group. The event counts within clusters are too small to get reliable
estimates of relative risk for treatment versus control groups
Table 8 Indicators of infection in the intervention and control clusters during the trial period
Characteristics Trial period
Intervention Control RR (95 % CI), p-valuea
Suspected maternal infection
Overall N,(%) 46/3,766 (1.2) 53/3,960 (1.3) N/A
<5th percentile N,(%) 6/181 (3.3) 5/158 (3.2) N/A
Possible severe bacterial infection (pSBI)
Overall N,(%) 508/3,725 (13.6) 460/3,904 (11.8) 1.13 (0.88–1.45), p = 0.3371
<5th percentile N,(%) 68/197 (34.5) 54/166 (32.5) 1.06 (0.82–1.36), p = 0.6530
aRR with corresponding 95 % CIs and p-values were calculated from generalized linear models accounting for the cluster-level variance and adjusted for
randomization strata. For maternal infection, the event counts within clusters were too small to get reliable estimates of relative risk
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